2020
Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis
Buettner S, Janssen Q, Suker M, Beumer B, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali M, Besselink M, Boone B, Chau I, Clarke S, Dillhoff M, El-Rayes B, Frakes J, Grose D, Hosein P, Jamieson N, Javed A, Khan K, Kim K, Kim S, Kim S, Ko A, Lacy J, Margonis G, McCarter M, McKay C, Mellon E, Moorcraft S. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Hepato Pancreato Biliary 2020, 22: s327. DOI: 10.1016/j.hpb.2020.04.310.Peer-Reviewed Original ResearchResectable pancreatic cancerNeoadjuvant FOLFIRINOXPancreatic cancerSystematic reviewFOLFIRINOXPatientsCancer
2018
Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
Janssen Q, Buettner S, Suker M, Margonis G, Paniccia A, El-Rayes B, Bahary N, Chau I, Hosein P, Ko A, Lacy J, Jamieson N, Tinchon C, Kim K, Besselink M, Wilmink J, Homs M, van Eijck C, Katz M, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Journal Of Clinical Oncology 2018, 36: e16207-e16207. DOI: 10.1200/jco.2018.36.15_suppl.e16207.Peer-Reviewed Original ResearchResectable pancreatic cancerNeoadjuvant FOLFIRINOXPancreatic cancerSystematic reviewFOLFIRINOXPatientsCancer